James Wilkerson, MD
Family Medicine · Sherwood, ARNPI 1083934632
Payments from drug & device makers
Across 311 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$714
- Astellas Pharma US Inc$607
- GSK$457
- AstraZeneca$456
- Novo Nordisk$445
- AbbVie$300
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,76697%
- Education$1643%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 47 | $714 |
| Astellas Pharma US Inc | 28 | $607 |
| GSK | 31 | $457 |
| AstraZeneca | 32 | $456 |
| Novo Nordisk | 30 | $445 |
| AbbVie(2 entities) | 14 | $300 |
| Lilly USA, LLC | 20 | $234 |
| Merck | 13 | $216 |
| Boehringer Ingelheim | 11 | $184 |
| Pfizer | 12 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $132 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $111 |
| Novartis | 7 | $106 |
| Sumitomo Pharma America, Inc. | 6 | $102 |
| Biohaven Pharmaceuticals, Inc. | 6 | $91 |
| Exact Sciences | 5 | $78 |
| Bayer | 4 | $65 |
| Ironwood Pharmaceuticals, Inc | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Antares Pharma, Inc. | 2 | $32 |
| Eisai Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Shield Therapeutics Inc | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Kinex Medical Company LLC | 1 | $5 |
How this compares
$4,930 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 145 | $149,895 |
| EliquisApixaban | 141 | $113,590 |
| TradjentaLinagliptin | 138 | $104,069 |
| JardianceEmpagliflozin | 90 | $80,648 |
| TrulicityDulaglutide | 74 | $77,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $59,480 |
| MounjaroTirzepatide | 47 | $50,113 |
| FarxigaDapagliflozin Propanediol | 53 | $45,460 |
| LinzessLinaclotide | 45 | $42,207 |
| MyrbetriqMirabegron | 42 | $31,087 |
| JanuviaSitagliptin Phosphate | 27 | $25,640 |
| XareltoRivaroxaban | 29 | $25,250 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $21,084 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $20,765 |
| Repatha SureclickEvolocumab | 20 | $17,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat, Stiolto Respimat | $184 | $210,902267 claims |
| Novo NordiskOzempic, Rybelsus | $445 | $166,992163 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $234 | $127,474121 claims |
| PfizerEliquis, Premarin | $168 | $116,237153 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $457 | $98,263153 claims |
| AstraZenecaFarxiga | $456 | $45,46053 claims |
| AbbVieLinzess | $300 | $42,20745 claims |
| MerckJanuvia, Janumet | $216 | $35,95440 claims |
| Astellas Pharma US IncMyrbetriq | $607 | $31,08742 claims |
| Johnson & JohnsonXarelto | $19 | $25,25029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Sherwood
- David GersonSherwood$119K
- Devon BallardSherwood$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.